

Patient + Provider Discussion Guide



Print and share this guide with your healthcare provider.

Talk to your provider about whether the Galleri® test is right for you.

Who is the Galleri test for?

- The Galleri test is recommended for adults with an elevated risk for cancer, such as those age 50 and older.
- The Galleri test is available by prescription only.
- Use of the Galleri test is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Here are topics to discuss with your healthcare provider:						
 The following lifestyle factors and health conditions may increase your risk for cancer. Check all that apply to you and discuss these with your provider 						
Age 50 years or older	☐ Immunodeficiency					
☐ Cancer survivor	☐ Immunosuppressive therapies after organ transplant					
Family history (parent, sibling, child)	☐ Increased BMI (Female $\ge 30 \text{ kg/m}^2 \text{ or Male } \ge 35 \text{kg/m}^2$)					
Genetic predisposition (e.g. BRCA)	Liver disease (Cirrhosis or chronic Hepatitis)					
☐ HPV infection	☐ Smoke or quit less than 10 years ago					
 Share your concerns about cancer and why early detection is important to you Express your interest in the Galleri test and ask if it is right for you 						

Pricing

Most health insurance companies do not cover the cost of the Galleri test. The cost varies depending on the healthcare practice or provider who orders your test. The list price for the Galleri test is \$949.

- You may be eligible for a 12-month, 0% interest, flexible payment plan. Call GRAIL Customer Service at 833-694-2553 to learn more.
- The Galleri test may be eligible for FSA or HSA coverage. Check with your plan to confirm eligibility.

Important Safety Information: The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of No Cancer Signal Detected does not rule out cancer. A test result of Cancer Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. **Rx only.**

Laboratory / Test Information: The GRAIL clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. The GRAIL clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

Information for your healthcare provider



Around 70% of cancer deaths are caused by cancers without recommended screening.^{4,5}



Only 5 out of >100 known cancer types have recommended screening options: breast, colorectal, cervical, lung (for those at risk), and prostate.^{4,6}

What is the Galleri test?

The Galleri multi-cancer early detection test screens for many of the deadliest cancers, including those with no recommended screening today. Galleri identifies DNA shed by cancer cells into the bloodstream before symptoms appear and can be taken annually. In the case of a Cancer Signal Detected result, the test will predict the most likely origin of the cancer signal, helping guide the diagnostic workup. Visit Galleri.com/50cancers to learn about what cancers the Galleri test screens for.

200,000+ tests completed, 11,000+ prescribing physicians across the US

Test performance validated through large-scale clinical studies with 20,000+ participants^{8,9}



2x the cancers detected

In a clinical study, adding the Galleri test to standard-of-care screening* approximately doubled the number of cancers** detected.



Low false positive rate (1 in 200 people without cancer) helps minimize unnecessary diagnostic procedures to confirm cancer.^{8,9}

**Cancers detected by the early version of the Galleri test that were confirmed by a diagnostic workup.

There are two possible test results:



No Cancer Signal Detected

This result means DNA fragments associated with cancer were not found in the blood sample. The test does not detect all cancers and not all cancers can be detected in the blood. This result does not completely rule out the possibility of cancer.

 $\textbf{Next steps:} \ \textbf{Continue with routine cancer screenings.}$



Cancer Signal Detected

This means DNA fragments often associated with cancer were found in the blood sample. This result will also include a prediction of the tissue type or organ associated with the cancer signal, called a **Cancer Signal Origin**.*

Next steps: This result is not a cancer diagnosis and requires follow-up diagnostic testing, which may include lab work or imaging to confirm cancer.

The Galleri test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests. See Important Safety Information on the previous page.

If the Galleri test is right for your patient, to order:





Receive the results

The results will be faxed to you about two weeks after receiving the sample at the GRAIL laboratory.

Learn more:



Galleri.com/hcp customerservice@grail.com 833-MY-GALLERI (833-694-2553)

^{*}Standard-of-care screening recommended by USPSTF (United States Preventive Services Task Force) for breast, cervical, colorectal, lung, and prostate cancer.

^{*}GRAIL, Inc. Data on file: VV-TMF-59592

^{1.} Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER Research Limited-Field Data, 21 Regs, 2020 Nov Sub (2000-2018) - Linked To County Attributes - Time Dependent (1990-2018) Income/Rurality, 1969-2019 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released 2021 Apr, based on the 2020 Nov submission. GRAIL Data on file GR-2023-0098 2. [GRAIL, LLC. Data on file: GA-2023-0205] 3. Cong Z, Ye X, Kurian AW. Elevated cancer risk among individuals with combinations of cancer-related risk factors: A large claims database analysis. American Society of Clinical Oncology (ASCO) [poster]; 2023 Jun 2-6. 4. US Preventive Services Task Force. A,B,C grade recommendations, cancer, screenings [cited 2023 Oct 23]. https://www.uspreventiveservicestaskforce.org/uspstf/topic_search_results 5. American Cancer Society. Estimated deaths per year in 2022. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065] 6. NIH, National Cancer Institute. What is cancer? [Updated 2021 Oct 11]. https://www.cancer.gov/about-cancer/understanding/what-is-cancer 7. American Cancer Society. Cancer facts & figures 2022. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html [GRAIL, LLC. Data on file: GA-2021-0065] 8. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-77. doi: 10.1016/j.annonc.2021.05.806 9. Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multi-cancer early detection (PATHFINDER): a prospective cohort study. Lancet. 2023;402:1251-1260. doi: 10.1016/S0140-6736(23)01700-2



Welcome

Thank you for choosing Galleri®, the first-of-its-kind multi-cancer early detection test.

Complete and fax this form

Please ensure the patient information, email, and address are correct and legible: the Galleri kit will be shipped to the patient.

Fax the completed Test Requisition Form (TRF) with cover sheet to this number:

650-999-9000


2 Expect a fax confirmation

Once we receive your order and verify your information, we will fax you a confirmation and your patient will receive a kit within a week.

→ Your test order is not placed until you receive a confirmation from us.

What to know

- GRAIL partners with labs nationwide for blood draw services. Your patient will be given information about convenient scheduling options when the collection kit arrives (Galleri.com/schedule).
- The First Responder list price of the test is \$649. Blood draw services are included in the price of the test when a Galleri-contracted site is used. We do not currently bill to insurance, please select 'Bill to Patient (Self-Pay)' on the Test Requisition Form.
- Your patient will be billed directly, once their sample has been processed and the results are made available. Please DO NOT provide a patient's credit card information. We will work with your patient directly to collect this information securely.
- Results will be sent to you via FAX to the number indicated on the TRF about 2 weeks from when the sample is received at our lab.





Reminder

Your patient is required to bring a completed TRF with them to their blood draw appointment.

We will send them a copy of the completed TRF via email. Please ensure the patient email address is correct on the form.

Contact GRAIL Customer Service



Galleri.com customerservice@grail.com



833-MY-GALLERI (833-694-2553)



FAX: 650-999-9000





Fax Cover

Fill in the blank fields below, and fax it along with the fully completed Test Requisition Form (TRF) to GRAIL Customer Service at 650-999-9000.

100				
	- 1			•
		 	_	٠.

Number of Pages (including cover sheet):

Recipient Information

To: GRAIL Customer Service

FAX Number: 650-999-9000

Sender Information

From:

Re: New Provider Galleri Order via Discussion Guide

FAX Number:

Phone Number:

Message:

CONFIDENTIAL INFORMATION ENCLOSED

STATEMENT OF CONFIDENTIALITY: This facsimile message contains private, privileged, and confidential information intended only for the sole use of the intended individual or entity named above. If the reader of this message is NOT the intended recipient, you are hereby notified that any review, use, dissemination, distribution, sharing, disclosure, or copying of this communication is strictly prohibited. If you are not the intended recipient, please immediately notify us by telephone at 650-771-9752 and destroy the original message. Thank you.





Test Requisition Form

ORDER ID	GRAIL ID
Expiration:	
Internal Use Only	Write in the GRAIL ID above or place the TRF label here

rest Requisition Form	Intern	al Use Only Write in the GRAIL II	D above or place the TRF label here			
SPECIMEN INFORMATION		Galleri® is a multi-cancer screening test and is reco				
Specimen Requirements: Collect Two 10mL Whole Blood, cfDNA Streck BCT* Blood Collection Tubes.	tion Date (MM/DD/YYYY) Time (24-hour)	with an elevated risk of cancer such as those age 50 is not recommended in individuals who are pregnan active cancer treatment. Please do not order the Ga	t, 21 years old or younger, or undergoing			
PATIENT INFORMATION		PATIENT'S CLINICAL INFORMATION				
First Name MI Date of birth (MM/DD/YYYY) Sex Assigned a Male F	Last Name at Birth MRN / Other ID Female	1 2 3 Check if applicable Solid organ Bone marrow	Patient Clinical History (Optional) Risk Factors for Cancer E.g. active smoking (or quit in the last 10 years) or exposure			
Street Address	State ZIP Code	transplant transplant Check if applicable (for information purpose only) Cancer survivor Cancer suspicion with Signs or Symptoms Active cancer with	Prior History of Cancer Cancer type and age at diagnosis			
Phone Number Ship a spe Email address	cimen collection kit to this Patient? Yes, to a different address (add to the comments)	Comments	Family History of Cancer Cancer type and relationship; hereditary cancer syndrome			
PROVIDER INFORMATION						
Ordering Provider's NPI (first-time order only) Ordering Provider's First Name Ordering Provider's First Name Clinic / Hospital Location Name Street Address City Phone Number Email Address PATIENT AUTHORIZATION (Optional) I authorize GRAIL (or a third party on GRAIL's behalf) to us include compensation to GRAIL. I understand that this aut GRAIL, but revoking my authorization will not affect any us laws may no longer apply and the information may be further than the same and the same an	e and disclose my identifiable health information to contac horization is voluntary and is not a condition to receiving t se or disclosure of my information that has already occurre	Provider attestation I attest that the patient has been informed about the purpose and health information. I obtained from the patient authoriza the disclosure to and indefinite retention and use by GRAIL, L identified sample, health information, and test result for rese purposes. I certify the following: I am authorized to order th ordering healthcare provider); and the test result will be use all patient information necessary for billing, and any related quality-related purposes. In addition, I attest that the patient has been informed If Galleri is billed to the patient's health insurer or plan, it may not be covered. The patient may be responsible for any amounts not paid by the plan and by submitting patient's credit card information on this form, the patient authorizes GRAIL to charge their credit card for Galleri. If the patient does not want their leftover deidentified sample used as described above, the patient may ask for sample destruction by writing to the GRAIL Customer Service Department within 60 days after the test results issuance.	tion for the: performance and billing of Galleri, and LC (GRAIL) and any third parties of the patient's dearch, product development, and quality-related is test (or was delegated authority by an authorized din the patient's care. I agree to provide to GRAIL clinical follow-up information for product-or of the following: 3 GRAIL may share test results and patient information with the insurer or plan, and the benefits will be made payable to GRAIL. Provider / Delegate Signature Date (MM/DD/YYYY) Date (MM/DD/YYYY) authorization by sending a written request to bornation has been disclosed, U.S. federal privacy			
BILLING INFORMATION						
Employer/Partnership Program	<u> </u>					
Bill to Clinic/Employer/Other If "Bill to Employer/Other," indicate the Employer/Partnership Program above.	Insurance Information Insurance Company	Check Box If Policyholder Name and Contact ID Number Gi	Information is SAME AS PATIENT ABOVE roup ID			
Bill to Health Insurance Complete the information on the right. Attach front and back copy of the insurance card.	Policyholder's First Name Policyholder's Street Address	MI Policyholder's Last Name Date of Birth (MM/DD/YYYY) City				
Bill to Patient (Self-pay) Report the credit card information below. Include the patient's email above.	State ZIP Code Phone Number	Patient Relationship	to Policyholder			
Patient's Credit Card Information Galleri® is a registered trademark of GRAIL, LLC. ©2021 GRAIL, LLC. All Rights Reserved CLAB-FRM-0017 V6.0						
Cardholder First Name	Cardholder Last Name	Tel: 833-MY-GALLERI (833-694-2553) Fax: 650-999-9000	LAB USE ONLY			
Credit Card Number (Amex, MC, Visa, Discover)	Expiration (MM/YY) CVV ZIP C	ode Email: customerservice@grail.com Web: galleri.com				